Image Coming Soon
GLP-1 Receptor Agonists for Weight Loss
FDA-approved GLP-1 peptides that work through your brain's appetite centers to suppress hunger and regulate metabolism. Clinical studies show up to 15-31% body weight reduction with these revolutionary medications.
Semaglutide and Tirzepatide are prescription medications that require proper medical evaluation. Our physicians assess your health history, current medications, and weight loss goals to determine which GLP-1 medication is right for you. We also monitor your progress and adjust dosing to minimize side effects and maximize results.
Our streamlined telehealth process makes it easy to get FDA-approved weight loss medications delivered to your door.
Book a convenient virtual consultation with one of our physicians. Available evenings and weekends.
Discuss your weight loss goals, medical history, and determine if GLP-1 therapy is appropriate for you.
If appropriate, your physician will prescribe Semaglutide or Tirzepatide and create a personalized dosing protocol.
Your medication ships directly to your home in temperature-controlled packaging with everything you need.
Semaglutide: 14.9% average weight loss at 68 weeks (STEP-1 trial). Oral version now available with 13.7% average weight loss.
Tirzepatide: Up to 31.6% body weight reduction in clinical trials - nearly double that of Semaglutide alone.
Semaglutide and Tirzepatide are GLP-1 receptor agonists - FDA-approved injectable medications that mimic the hormone GLP-1, which is released in the gut after eating. They help regulate blood sugar, slow stomach emptying, and significantly reduce appetite, leading to substantial weight loss.
Clinical studies show impressive results: Semaglutide (2.4mg) demonstrated 14.9% body weight reduction at 68 weeks. Tirzepatide has shown even greater results with up to 31.6% body weight reduction due to its dual-receptor approach targeting both GLP-1 and GIP receptors.
GLP-1 peptides work primarily through the brain's appetite centers to suppress hunger while also delaying gastric emptying, which prolongs feelings of fullness. This combined effect leads to a gradual, sustainable reduction in calories consumed.
Semaglutide targets only the GLP-1 receptor, while Tirzepatide is a dual-agonist that activates both GLP-1 and GIP receptors. This multi-receptor approach creates synergistic effects, typically producing greater weight loss with Tirzepatide.
Yes, GLP-1 medications improve outcomes for cardiovascular health, kidney function, liver health, and sleep apnea. Benefits include lower blood pressure, improved cholesterol, reduced fatty liver disease, and decreased risk of heart disease.
Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite - especially when starting or increasing doses. These typically improve over time. Your physician will start with a low dose and gradually increase to minimize side effects.
Schedule your telehealth consultation today. Our physicians will determine if GLP-1 therapy is right for you and create a personalized weight loss plan.